Page last updated: 2024-10-31

nabumetone and Hypereosinophilic Syndrome

nabumetone has been researched along with Hypereosinophilic Syndrome in 1 studies

Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.
nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.

Hypereosinophilic Syndrome: A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Pitt, M1
Davies, MK1
Brady, AJ1

Other Studies

1 other study available for nabumetone and Hypereosinophilic Syndrome

ArticleYear
Hypereosinophilic syndrome: endomyocardial fibrosis.
    Heart (British Cardiac Society), 1996, Volume: 76, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Endomyocardial Fibrosis; Female; Heart; Humans;

1996